| Literature DB >> 31701365 |
M A Segui1, J J Cruz2, E Alba3, J Feliu4, C Jara5, F Rivera6, A Rodriguez Lescure7, A Lorenzo8, M Martin9.
Abstract
PURPOSE: The Spanish Society of Medical Oncology (SEOM, for its Spanish acronym) would like to attest to the relevance of training in Oncology as part of the undergraduate education in Medicine program and issue recommendations to improve said training, with the aim of responding better to the challenges that cancer poses to our society.Entities:
Keywords: Education; Future; Oncology; Recommendations; SEOM; Spain; Undergraduate
Mesh:
Year: 2019 PMID: 31701365 PMCID: PMC7260140 DOI: 10.1007/s12094-019-02230-8
Source DB: PubMed Journal: Clin Transl Oncol ISSN: 1699-048X Impact factor: 3.405
Fig. 1Percentage of medical schools with a specific program in Oncology, with or without an independent subject
Teaching modalities of the specific Medical Oncology program
| Modality | No. medical schools | % |
|---|---|---|
| Independent compulsory subject with six credits | 1 | 2 |
| Independent compulsory subject with fewer than six credits | 5 | 12 |
| Independent elective subject | 2 | 5 |
| Joint subject with another specialty, with between three and four credits dedicated to Medical Oncology, but with an independent examen | 6 | 15 |
| Joint subject with another specialty, with between three and 4.5 credits | 16 | 39 |
| Joint subject with another specialty and FEWER than three MO credits | 9 | 22 |
| No specific program in Medical Oncology | 2 | 5 |
| Total | 41 | 100 |
Fig. 2Organization of the contents of palliative care in undergraduate medical education
Average number of credits dedicated to Medical Oncology according to the type of subject
| Average credits overall subject | Average credits in MO* | |
|---|---|---|
| Independent subjects | 3.81 | 3.81 |
| Joint subjects | 7.21 | 2.96 |
| Overall | 6.51 | 3.16 |
*Estimated according to the hours of teaching dedicated to Medical Oncology
Fig. 3Percentage of subjects with different training modalities
Subjects with Medical Oncology content that offer the option of carrying out clinical practice on a Medical Oncology service
| Practicum on Medical Oncology service | No. of subjects | % |
|---|---|---|
| Yes | 27 | 69 |
| Possible | 3 | 8 |
| No | 6 | 15 |
| Lacking information | 3 | 8 |
| Total | 39 | 100 |
Fig. 4Evaluation methodology applied in subjects with MO content (%)
Comparison between the 2013 analysis of the “Formación de pregrado en Oncología Una asignatura pendiente” and the current analysis
| Criterium | 2003 | 2013 | 2013 Recommendation | 2016 |
|---|---|---|---|---|
| Specific, independent, compulsory program | 33.33% | 41.66% | Specific, distinct curriculum for Medical Oncology. Core/ mandatory subject | 29% |
| Specific, non-independent, compulsory program | 12.50% | 25% | 61% | |
| Specific, compulsory program | 45.83% | 66.66% | 90% | |
| Specific, independent, elective program | 29% | 13.88% | 5% | |
| Total credits (mean) | Five cred. LOU | 3.5 ECTS | Six ECTS | 3.2 ECTS |
| Academic year for the 5–6 years program/3 years educational program | 5th or 6th | 4th, 5th, or 6th | 5th or 6th | 3th, 4th, 5th, or 6th |
| Medical Oncology instructor | 40% | 69% | Promote instructors having a specific profile and clinical dedication to Oncology | 90% |
| Independent examination | 66% | 72% | Independent grading | 34% |
SEOM’s recommendations for the organization of Medical Oncology programs
Program integrated in a mandatory subject Having at least 4–6 specific ECTS, depending upon whether palliative care content is included In a subject taught in the last years of the undergraduate education program, preferably in the 5th year, when the student already has a general view of the disease Having an instructor who is a medical oncologist in 100% of the cases, who imparts knowledge about the clinical approach to the patient in routine practice (symptomatology, toxicities, support treatment, etc.) and contributes an integral view of cancer treatment Having aims specifics for the training of competences appropriate to primary care physicians and future specialists in different diseases having greater contact with patients with cancer, avoiding an excessive workload of highly specialized knowledge Coordinated with the content about cancer in other Medical Pathology and Surgical Pathology subjects, thereby preventing redundancies or commissions Reinforce the importance of the clinical content of Oncology, with a specific system and the aim of evaluating competences With the option of practical in Medical Oncology services in 100% of the subjects or rotations |
Program of Medical Oncology proposed by SEOM
| Medical Oncology | |
|---|---|
| KNOW | |
| Recognize, diagnose, and guide management | Only know about |
| 1. Tumor disease: Gnoseologic diagnosis and diagnosis of extension. Prognostic factors and staging factors | 1. Cell and molecular biology of cancer |
| 2. Epidemiology of cancer and risk factors | 2. Carcinogenesis |
| 3. Primary and secondary prevention | 3. Growth of the tumor cell |
| 4. Hereditary cancer and genetic counseling | 4. Mechanisms of tumor invasion and metastasis |
| 5. Acute tumor complications: superior vena cava syndrome. Spinal cord compression syndrome. Intracranial hypertension syndrome. Hypercalcemia | |
| 6. Paraneoplastic syndromes (endocrine, neurological, hematological, dermatological, osteoarticular, and other manifestations) | |
| 7. Systemic treatment for cancer: chemotherapy | |
| 8. Systemic treatment for cancer: hormonotherapy | |
| 9. Systemic treatment for cancer: immunotherapy and biological therapies | |
| 10. Evaluation of response to treatment and effects on quality of life (e.g., RECIST, WHO). Clinical trials in Oncology | |
| 11. Acute toxicity of antineoplastic treatment | |
| 12. Support treatment for the patient with neoplasia: general concepts | |
| 13. Support treatment for the patient with neoplasia. Infections in the patient with cancer | |
| 14. Support treatment for the patient with neoplasia. Pain treatment | |
| 15. Support treatment for the patient with cancer. Anemia. Cachexia | |
| 16. Control of syndromes in terminal disease. Sedation | |
| 17. Lung cancer. Natural history, prognostic factors, staging, and treatment strategy | |
| 18. Breast cancer. Natural history, prognostic factors, staging, and treatment strategy | |
| 19. Cancer of the stomach, pancreas, and bile ducts. Natural history, prognostic factors, staging, and treatment strategy | |
| 20. Colorectal cancer. Natural history, prognostic factors, staging, and treatment strategy | |
| 21. Ovarian cancer. Natural history, prognostic factors, staging, and treatment strategy | |
| 22. Head and neck cancer. Natural history, prognostic factors, staging, and treatment strategy | |
| 23. Prostate cancer. Natural history, prognostic factors, staging, and treatment strategy | |
| 24. Bladder, urinary tract, and kidney cancers. Natural history, prognostic factors, staging, and treatment strategy | |
| 25. Germ cell tumors. Natural history, prognostic factors, staging, and treatment strategy | |
| 26. Cancer of the cervix and endometrium. Natural history, prognostic factors, staging, and treatment strategy | |
| 27. Sarcomas. Natural history, prognostic factors, staging, and treatment strategy | |
| 28. Melanomas. Natural history, prognostic factors, staging, and treatment strategy | |
| 29. Tumors of the central nervous system. Natural history, prognostic factors, staging, and treatment strategy | |
| 30. Cancer of unknown origin. Natural history, prognostic factors, staging, and treatment strategy | |